• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Tirzepatide reduces body weight and improves cardiometabolic function in patients with obesity

byBryant LimandKiera Liblik
July 22, 2022
in Cardiology, Chronic Disease, Endocrinology, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Tirzepatide treatment significantly reduced body weight and fat composition in obese patients while improving cardiometabolic risk factors and physical function.

2. The frequency of serious adverse events was not significantly different between the tirzepatide and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The global prevalence of obesity is increasing substantially. This is detrimental to global health as obesity is associated with several chronic conditions such as cardiovascular disease and type 2 diabetes. Glucagon-like peptide-1 (GLP-1) agonists, which target food-stimulated hormonal pathways, are an emerging drug class for treating obesity and diabetes. Glucose-dependent insulinotropic polypeptide (GIP) receptor agonists also regulate energy balance via similar mechanisms. A combination of these two drug classes is hypothesized to produce synergistic effects on weight loss. The present phase three randomized control trial evaluated the efficacy and safety of various doses of tirzepatide, a dual GLP-1 and GIP receptor agonist, as compared to placebo control. In addition to standard lifestyle intervention, participants received once weekly subcutaneous doses of tirzepatide (5mg, 10mg, and 15mg) or a placebo for 72 weeks. Participants were followed for four weeks after the regimen. Tirzepatide significantly reduced body weight and fat composition compared to placebo. Tirzepatide treatment was also associated with improvements in cardiometabolic risk factors and physical function. A higher proportion of participants in the treatment group experienced adverse events, of which the most common were gastrointestinal-related symptoms. However, the prevalence of serious adverse events was statistically similar between groups. As a limitation, the effect of tirzepatide on overweight (body-mass index (BMI) of 27 to 30) patients is not well supported as overweight participants only made up 5.5% of the study. Efficacy and safety data may also have limited generalizability to older patients due to the high proportion of young participants in the study cohort.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: In the present study, adult patients with obesity (n=2,539) were randomly assigned in a 1:1:1:1 ratio into tirzepatide (5mg, 10mg, or 15mg) or placebo groups. Participants were administered tirzepatide or placebo subcutaneously once weekly concurrently with a standard lifestyle intervention for 72 weeks. Safety data were collected during a four-week follow-up period for participants without prediabetes. In total, 86% of participants completed the trial treatment. At baseline, the majority of participants had a BMI of over 30 (94.5%) and did not have prediabetes (59.4%). At week 72, weekly 5mg, 10mg, and 15mg dose of tirzepatide resulted in a -15% (95% Confidence Interval [CI], -15.9 to -14.2), -19.5% (95% CI, -20.4 to -18.5), and -20.9% (95% CI, -21.8 to -19.9) weight reduction, respectively. Placebo resulted in a -3.1% (95% CI, -4.3 to -1.9) weight reduction. All three doses of tirzepatide resulted in a significant weight reduction compared to the placebo (p<0.001 for all comparisons to placebo). Body fat composition was also reduced by 33.9% in the tirzepatide group compared to 8.2% in the placebo group. Tirzepatide treatment was associated with improvements in cardiometabolic risk factors, including waist circumference, blood pressure, fasting insulin level, and lipid levels. Participants in the tirzepatide group also had improved perception of their physical function as assessed by the 36-Item Short Form Health Survey. Finally, adverse events were reported in 78.9% to 81.8% of participants in the tirzepatide group compared to 72.0% of participants in the placebo group. The most common adverse events were gastrointestinal. However, the prevalence of serious adverse events was similar between groups. This clinical trial supports the efficacy and safety of tirzepatide, a dual GLP-1 and GIP agonist, as a treatment for obesity in younger patients.

Image: PD

RELATED REPORTS

Supplemental vitamin D does not reduce risk of fractures in older adults

#VisualAbstract: Intravenous infusion of fluid bolus does not decrease incidence of cardiovascular collapse during tracheal intubation

Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-Year clinical outcomes

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologycardiometabolic riskchronic diseasediabetesendocrinologyGastroenterologyGIP agonistGLP-1 agonistobesityTirzepatide
Previous Post

Understanding purpose in life in older adults may require a multifaceted approach

Next Post

#VisualAbstract: Pharmacogenomic testing in antidepressant selection for Major Depressive Disorder reduces prescription of medications with drug-gene interactions

RelatedReports

Proton pump inhibitor use in pediatric patients may increase fracture risk
Chronic Disease

Supplemental vitamin D does not reduce risk of fractures in older adults

August 5, 2022
#VisualAbstract: Intravenous infusion of fluid bolus does not decrease incidence of cardiovascular collapse during tracheal intubation
StudyGraphics

#VisualAbstract: Intravenous infusion of fluid bolus does not decrease incidence of cardiovascular collapse during tracheal intubation

August 4, 2022
Rivaroxaban after TAVR linked with increased risk of adverse events compared to antiplatelet therapy
Cardiology

Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-Year clinical outcomes

August 3, 2022
Chronic Disease

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

August 2, 2022
Next Post
#VisualAbstract: Pharmacogenomic testing in antidepressant selection for Major Depressive Disorder reduces prescription of medications with drug-gene interactions

#VisualAbstract: Pharmacogenomic testing in antidepressant selection for Major Depressive Disorder reduces prescription of medications with drug-gene interactions

Lower target oxygen saturation in extremely preterm infants appears safe

Racial and ethnic discrepancies in pulse oximetry performance associated with reduced oxygen supplementation

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

4% albumin solution nonsuperior to Ringer acetate for volume replacement in cardiac surgery with cardiopulmonary bypass

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age
  • CT-guided percutaneous lung biopsies more effective for larger pulmonary nodules [Classics Series]
  • Supplemental vitamin D does not reduce risk of fractures in older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.